These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26646948)

  • 1. Identification of Major Signaling Pathways in Prion Disease Progression Using Network Analysis.
    Newaz K; Sriram K; Bera D
    PLoS One; 2015; 10(12):e0144389. PubMed ID: 26646948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systems approach to prion disease.
    Hwang D; Lee IY; Yoo H; Gehlenborg N; Cho JH; Petritis B; Baxter D; Pitstick R; Young R; Spicer D; Price ND; Hohmann JG; Dearmond SJ; Carlson GA; Hood LE
    Mol Syst Biol; 2009; 5():252. PubMed ID: 19308092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene regulatory network analysis supports inflammation as a key neurodegeneration process in prion disease.
    Crespo I; Roomp K; Jurkowski W; Kitano H; del Sol A
    BMC Syst Biol; 2012 Oct; 6():132. PubMed ID: 23068602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of neurotoxicity of pathological prion protein.
    Castilla J; Hetz C; Soto C
    Curr Mol Med; 2004 Jun; 4(4):397-403. PubMed ID: 15354870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and infectious prion diseases.
    Prusiner SB
    Arch Neurol; 1993 Nov; 50(11):1129-53. PubMed ID: 8105771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive transcriptional profiling of prion infection in mouse models reveals networks of responsive genes.
    Sorensen G; Medina S; Parchaliuk D; Phillipson C; Robertson C; Booth SA
    BMC Genomics; 2008 Mar; 9():114. PubMed ID: 18315872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
    Prasad KN; Bondy SC
    Curr Aging Sci; 2019; 11(4):216-225. PubMed ID: 30636622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prions: pathogenesis and reverse genetics.
    Aguzzi A; Klein MA; Montrasio F; Pekarik V; Brandner S; Furukawa H; Käser P; Röckl C; Glatzel M
    Ann N Y Acad Sci; 2000; 920():140-57. PubMed ID: 11193143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered distribution, aggregation, and protease resistance of cellular prion protein following intracranial inoculation.
    Ward A; Hollister JR; Choi YP; Race B; Williams K; Shoup DW; Moore RA; Priola SA
    PLoS One; 2019; 14(7):e0219457. PubMed ID: 31291644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
    Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
    J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prion disease tempo determined by host-dependent substrate reduction.
    Mays CE; Kim C; Haldiman T; van der Merwe J; Lau A; Yang J; Grams J; Di Bari MA; Nonno R; Telling GC; Kong Q; Langeveld J; McKenzie D; Westaway D; Safar JG
    J Clin Invest; 2014 Feb; 124(2):847-58. PubMed ID: 24430187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the histo-molecular pathology of human prion disease.
    Baiardi S; Rossi M; Capellari S; Parchi P
    Brain Pathol; 2019 Mar; 29(2):278-300. PubMed ID: 30588685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel form of human disease with a protease-sensitive prion protein and heterozygosity methionine/valine at codon 129: Case report.
    Rodríguez-Martínez AB; Garrido JM; Zarranz JJ; Arteagoitia JM; de Pancorbo MM; Atarés B; Bilbao MJ; Ferrer I; Juste RA
    BMC Neurol; 2010 Oct; 10():99. PubMed ID: 20973975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prion peptide 106-126 as a model for prion replication and neurotoxicity.
    Singh N; Gu Y; Bose S; Kalepu S; Mishra RS; Verghese S
    Front Biosci; 2002 Apr; 7():a60-71. PubMed ID: 11897566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTIR-microspectroscopy of prion-infected nervous tissue.
    Kretlow A; Wang Q; Kneipp J; Lasch P; Beekes M; Miller L; Naumann D
    Biochim Biophys Acta; 2006 Jul; 1758(7):948-59. PubMed ID: 16887095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fundamentals of prion diseases and their involvement in the loss of function of cellular prion protein.
    Sakudo A; Ikuta K
    Protein Pept Lett; 2009; 16(3):217-29. PubMed ID: 19275734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular clues to pathogenesis in prion diseases.
    Laurent M; Johannin G
    Histol Histopathol; 1997 Apr; 12(2):583-94. PubMed ID: 9151145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-Edge Sword of Sustained ROCK Activation in Prion Diseases through Neuritogenesis Defects and Prion Accumulation.
    Alleaume-Butaux A; Nicot S; Pietri M; Baudry A; Dakowski C; Tixador P; Ardila-Osorio H; Haeberlé AM; Bailly Y; Peyrin JM; Launay JM; Kellermann O; Schneider B
    PLoS Pathog; 2015 Aug; 11(8):e1005073. PubMed ID: 26241960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent amplification of co-infected long incubation period low conversion efficiency prion strains.
    Eckland TE; Shikiya RA; Bartz JC
    PLoS Pathog; 2018 Oct; 14(10):e1007323. PubMed ID: 30335854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Amyloidgenesis in prion disease].
    Tsuboi Y
    Brain Nerve; 2014 Jul; 66(7):849-55. PubMed ID: 24998829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.